Extension Study for Patients Who Have Participated in a BMN 701 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 15, 2011

Primary Completion Date

September 9, 2016

Study Completion Date

September 9, 2016

Conditions
Pompe Disease
Interventions
BIOLOGICAL

BMN 701

GILT-tagged recombinant human GAA

Trial Locations (12)

1142

Auckland City and Starship Children's Hospital, Auckland

4029

Royal Brisbane and Women's Hospital, Herston

5006

Royal Adelaide Hospital, North Adelaide

32610

University of Florida College of Medicine, Gainesville

33606

Tampa General Hospital, Tampa

55131

Villa Metabolica, ZKJM MC University Mainz, Mainz

66160

University of Kansas Medical Center, Kansas City

75013

Hôpital Pitié-Salpêtrière, Paris

92103

Univ of California San Diego School of Medicine, San Diego

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

NW3 2QG

Royal Free Hospital, London

M5 5AP

Salford Royal NHS Foundation Trust, Salford

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY